Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Veracyte, Inc (VCYT) operate in?
Veracyte, Inc belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Veracyte, Inc (VCYT) current stock price?
As of the latest data, Veracyte, Inc stock price is $48.20, with a previous close of $47.93. Veracyte, Inc gained $0.27 in the last trading session, representing a 0.56% increase.
What is Veracyte, Inc (VCYT) current market capitalization?
Veracyte, Inc market cap is approximately 3.87 billion.
What is Veracyte, Inc (VCYT) Earnings Per Share (EPS)?
The trailing EPS is $1.31, and the forward EPS is $1.95.
What is Veracyte, Inc (VCYT) Price-to-Earnings (P/E) ratio?
Veracyte, Inc current P/E ratio is 36.79, with a forward P/E of 24.72.
What is Veracyte, Inc (VCYT) EBITDA?
Veracyte, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 24.28 million.
Does Veracyte, Inc (VCYT) pay dividends?
No. Veracyte, Inc does not pay a dividend.
How did Veracyte, Inc (VCYT) perform in its most recent earnings report?
In the last report (June 30, 2026), Veracyte, Inc posted an EPS surprise of 27.59% and a revenue surprise of 4.05%.
When is Veracyte, Inc (VCYT) next earnings report?
Veracyte, Inc is expected to release its next earnings report on September 30, 2026.
What is Veracyte, Inc (VCYT) beta (volatility) score?
Veracyte, Inc has a beta of 1.947, suggesting it is more volatile than the market.
